Omega Diagnostics Group PLC

14 December 2021


("Omega" or the "Company" or the "Group")

Confirmation of detection of Omicron variant

VISITECT(R) COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd ("Mologic") that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios(R) Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT(R) COVID-19 antigen test.

Colin King, CEO, Omega Diagnostics, said: "We are very pleased be in a position to confirm that the VISITECT(R) COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT(R) COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use."


  Omega Diagnostics Group PLC                                         www.omegadx.com 
  Colin King, Chief Executive Officer                                 via Walbrook PR 
  Chris Lea, Chief Financial Officer 
  finnCap Ltd                                                      Tel: 020 7220 0500 
  Geoff Nash/Edward Whiley (Corporate 
  Alice Lane/ Charlotte Sutcliffe (ECM) 
  Walbrook PR Limited                      Tel: 020 7933 8780 or omega@walbrookpr.com 
  Paul McManus                                                     Mob: 07980 541 893 
  Lianne Applegarth                                                Mob: 07584 391 303 
  Sam Allen                                                        Mob: 07502 558 258 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

December 14, 2021 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2022 a May 2022 Haga Click aquí para más Gráficas Omega Diagnostics.
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De May 2021 a May 2022 Haga Click aquí para más Gráficas Omega Diagnostics.